John Gribben is Hamilton Fairley Professor of Medical Oncology at Barts Cancer Institute, Barts and The London School of Medicine, Queen Mary University of London, UK. After doctoral studies at University College London, where he was the recipient of a Wellcome Trust Fellowship Award, he received a Fogarty International Fellowship to continue postdoctoral training at the Dana-Farber Cancer Institute, Harvard Medical School in Boston, USA. In 1992, Professor Gribben was appointed to the faculty at Harvard Medical School, where he remained as Associate Professor of Medicine and an attending physician until returning to London in 2004. He is an internationally recognized translational cancer researcher and the author of more than 380 manuscripts and 60 book chapters. Professor Gribben’s primary research interests include the management of lymphoma and chronic lymphocytic leukemia, immunotherapy of cancer (including stem-cell transplantation), the identification of tumor antigens, and eradication of minimal residual disease. He was recently awarded with the prestigious Binet-Rai Medal for his outstanding contribution to Chronic Lymphocytic Leukaemia (CLL) research and acknowledged for his work on the impact of CLL on the host immune system and delineating the mechanisms for this and for his pioneering work on stem cell transplantation in CLL.
You can see my upcoming and previous webinars here.